Meeting
2018 ASCO Annual Meeting
A phase II trial of enzalutamide, docetaxel and androgen deprivation therapy (ENZADA) in patients with metastatic castrate sensitive prostate cancer (mCSPC).
Authors
Earle Frederick Burgess
Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC
Earle Frederick Burgess , Claud Grigg , Peter E Clark , Danielle Boselli , James Thomas Symanowski , Derek Raghavan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03246347
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS5094)
DOI
10.1200/JCO.2018.36.15_suppl.TPS5094
Abstract #
TPS5094
Poster Bd #
317a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).
First Author: Earle F Burgess
Poster
2023 ASCO Annual Meeting
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Charles J. Ryan
Poster
2022 ASCO Genitourinary Cancers Symposium
Evaluation of tumor genomic variants in Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide: Protocol of a phase 4 study (CUARTET).
First Author: Hirotsugu Uemura
Poster
2024 ASCO Genitourinary Cancers Symposium
A multicohort phase 2 trial of ADT, docetaxel plus nivolumab in patients with de novo metastatic hormone-sensitive prostate cancer enriched for inflamed tumors and DNA damage repair defects.
First Author: Xiao X. Wei